David Huberman works closely with Israeli and domestic clients, representing issuers and underwriters on capital raising transactions, including private and public offerings. He regularly represents Israeli companies in their initial public offerings on U.S. stock exchanges and advises on ongoing compliance with U.S. securities laws. David’s clients include pharmaceutical and technology companies currently traded, or on their way to the Nasdaq.
Concentrations
•Capital markets
•Initial public offerings (IPOs)
•Public and private offerings of equity and debt
•Dual listings and American depositary facilities
•Securities Exchange Act reporting and compliance obligations
•Israeli practice
Recognition & Leadership
Awards & Accolades
•Listed, IFLR1000: Israel: Capital Markets, 'Notable Practitioner,' 2024-2025
•Chambers Global, Corporate/M&A: International Firms (Expertise Based Abroad), Team Member, 2022-2024
•Listed, The Best Lawyers in America, 'Ones to Watch,' Securities/Capital Markets, 2023-2024
•BDICode (Israel)
•Recognized, International Commercial, Prominent Leaders, 2016-2024
•Recognized, Capital Markets, Prominent Leaders, 2024
•Recognized, Hi-Tech, Prominent Leaders, 2021-2024
•Dun's 100 (Israel)
•Recognized, International Commercial, Prominent Team, 2022-2025
•Recognized, Hi-Tech, Notable Law Firm, 2022-2025
•Recognized, Capital Markets, Notable Law Firm, 2025
•LMG Life Sciences EMEA Awards:
•Shortlisted, Israeli Firm of the Year, 2025
•LegallyIsrael100
•Ranked, Capital Markets, 2022, 2025
•Recognized, High-Tech, 2025
•Listed, The Legal 500, Israel, 2020